ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 679

ZAP70+ B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis

Elisa Gremese, Barbara Tolusso, Laura Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, Nephritis, remission and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: To analyze differences in B cells subsets distribution in patients with renal systemic lupus erythematosus (SLE). To define  possible cellular biomarkers of active nephritis and of remission in renal disease in SLE patients.

Methods: 60 SLE patients with renal involvement 49 females (82%); mean age 36.9±11.0 years; 37 with active disease and 23 with disease in remission) were analyzed for the distribution of circulating peripheral blood B cell subpopulations by staining for surface markers CD45, CD19, CD38, IgD, CD27 (CD27/IgD classification (Sanz et al. SeminImmunol 2008) and intracellular marker ZAP-70 (Tolusso et al. ClinImmunol 2009) by flow cytometry. All patients had a WHO class III or  IV nephritis diagnosed by renal biopsy. Patients with active nephritis were recruited at the renal disease onset, while patients in remission were recruited if the nephritis was in stable remission for at least 12 months. Fourteen patients with active disease at the study entry were reassessed for PB B cell subpopulations at the time of renal remission (nephritis remission criteria in at least two consecutive observations and on an oral steroid dosage<7.5 mg/day).

Results: The 37 subjects with active renal involvement showed higher percentages of CD19/ZAP70+ cells compared to 23 patients with nephritis remission (13.1±10.5% vs5.4±4.5%, respectively; p=0.002), as well as of plasmablasts (CD27/CD38+ cells: 10.6±7.4% vs 6.3±5.8%, respectively; p=0.03).There was no differences in other B cells subpopulations between active and inactive lupus nephritis.

In the 60 SLE renal patients, the percentage of CD19+/ZAP-70+ cells directly correlated with disease activity index (SLEDAI) (r=0.44, p=0.002), inversely with complement fractions C3 and C4 (C3: r=-0.44, p=0.001, C4: -0.45, p=0.001), with the number of lymphocytes (r=-0.55, p<0.001) and of the CD19+ B cells (r=-0.61, p<0.001). Moreover, the pool of ZAP70+ B cells directly correlated with the memory cells subsets (CD27+IgD-: r=0.41, p=0.002, CD27-IgD-: r=0.34, p=0.01) and with plasmablasts (r=0.39, p=0.004) and inversely with naive B cells (CD27-IgD+: r=-0.48, p<0.001). The 14 patients evaluated in the follow-up showed a significant reduction of the percentage of ZAP70+ B cells at remission (4.3±2.8%) with respect to nephritis onset (14.4±11.6%, p=0.002), as well as of the plasmablasts (CD19+/CD27+CD38+: 10.7±8.0% at baseline vs 5.7±2.9% at remission; p=0.05).

Conclusion: The pool of CD19+/ZAP70+ cells is associated with SLE activity parameters (SLEDAI, low complement, low lymphocytes and CD19+ count) and with the B cell memory compartment in SLE patients with renal involvement. The expansion of ZAP70+ B cells and plasmablasts characterizes active renal disease and their reduction is associated with the remission state, suggesting their possible role as biomarker in SLE nephritis.


Disclosure:

E. Gremese,
None;

B. Tolusso,
None;

L. Messuti,
None;

M. Nowik,
None;

S. Canestri,
None;

L. Petricca,
None;

M. R. Gigante,
None;

G. Ferraccioli,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/zap70-b-cells-and-plasmablasts-as-markers-of-disease-activity-and-remission-in-systemic-lupus-erythematosus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology